SASiriluck Anunnatsiri

Siriluck Anunnatsiri

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Siriluck Anunnatsiri has a total of 114 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • A Randomized Controlled Trial of Cefiderocol Versus Standard Therapy for Gram-negative Bacterial Bloodstream Infections: Benefit and Risk Assessment Using Desirability of Outcome Ranking and Generalized Pairwise Comparisons

    by Melissa J Hardy, Patrick N A Harris, Yin Mo, Mark D Chatfield, Helmi Sulaiman, Po-Yu Liu, Mesut Yilmaz, Zeti Norfidiyati Salmuna, Mohd Zulfakar Mazlan, Siriluck Anunnatsiri, et al.

    Background: Gram-negative bacterial bloodstream infections (BSIs) cause substantial mortality and morbidity. The GAME CHANGER trial compared cefiderocol with standard of care (SOC) for Gram-negative BSIs, with 14-day all-cause mortality (ACM) as the primary endpoint. We evaluated cefiderocol versus SOC integrating efficacy and safety outcomes using desirability of outcome ranking (DOOR) and generalized pairwise comparisons (GPC). Methods: Composite endpoints were prespecified before data review. The DOOR endpoint included treatment failure, infectious complications, serious adverse events, and 90-day ACM, with functional improvement as a tiebreaker. The GPC approach included ACM at 30 days, clinical failure, serious adverse events, functional improvement, and hospitalization duration. Analyses were conducted in the main population and carbapenem-resistant subset. Results: The DOOR composite in the main population resulted in a probability of a more desirable outcome with cefiderocol of 50.4% (95% confidence interval [CI], 45.6–55.1). The analysis with GPC resulted in a win ratio and win odds of 1.04 (95% CI, 0.85–1.28) and net treatment benefit of 2.1% (95% CI, −8.0 to 12.2). In the carbapenem-resistant subset, the DOOR probability with cefiderocol was 46.8% (95% CI, 37.4–56.1). The analysis with GPC resulted in a win ratio and win odds of 0.90 (95% CI, 0.60–1.34) and net treatment benefit of −5.4% (95% CI, −25.3 to 14.5). Conclusions: In adults with Gram-negative bacterial BSIs, cefiderocol was not superior to SOC based on DOOR or GPC analyses in both the main population and carbapenem-resistant subset. Integrating efficacy, safety, and functional outcomes using these approaches provides a more comprehensive assessment than mortality alone.

  • Open Access

    Increased Inflammatory Responses in Patients With Active Disseminated Non-Tuberculous Mycobacterial Infection and High Anti-Interferon-Gamma Autoantibodies

    by Pattaraporn Srisai, Chanchai Hongsa, Yothin Hinwan, Varis Manbenmad, Ploenchan Chetchotisakd, Siriluck Anunnatsiri, Kiatichai Faksri, Todsapol Techo, Kanin Salao, Steven W. Edwards, et al.

    Srisai P, et al. Immune Netw. 2024 Oct;24(5):e36. https://doi.org/10.4110/in.2024.24.e36


  • Open Access

    Colistin-Induced Acute Kidney Injury and the Effect on Survival in Patients with Multidrug-Resistant Gram-Negative Infections: Significance of Drug Doses Adjusted to Ideal Body Weight

    by Nittha Arrayasillapatorn, Palinee Promsen, Kittrawee Kritmetapak, Siriluck Anunnatsiri, Wijittra Chotmongkol, Sirirat Anutrakulchai

    Background. Colistin is a lifesaving treatment for multidrug-resistant Gram-negative bacterial (MDR-GNB) infections along with its well-known nephrotoxicity. The controversy of colistin-induced acute kidney injury (AKI) on mortality is noted. This study aimed to determine the risk factors and impact of AKI on the survival and significance of colistin dosage. Methods. A retrospective cohort study was performed in adult patients who received intravenous colistin for MDR-GNB treatment between June 2015 and June 2017. Factors influencing colistin-induced AKI and survival were evaluated by Cox regression analysis. Cut-off levels of the colistin dose per ideal body weight (IBW) that significantly affected clinical outcomes were assessed with linearity trends and receiver operating characteristic analyses. Results. AKI occurred in 68.5% of 412 enrolled patients with an incidence rate of 10.6 per 100 patients-days and a median time was 6 (3–13) days. Stages I–III of AKI were 38.3, 24.5, and 37.2%. Factors associated with colistin-induced AKI were advanced age, high serum bilirubin, AKI presented before colistin administration, increased daily colistin doses per IBW, and concomitant use of nephrotoxic drugs. Colistin-induced AKI was related to mortality (HR 1.74, 95% CI 1.06–2.86, ). In the non-AKI before colistin usage subgroup, the total dose and total dose/IBW were >1,500–2,000 mg and 30–35 mg/kg to benefit mortality reduction but were 4.5 mg/kg/day also increased the risk of AKI. In the AKI developed before colistin subgroup, the cut-off values of total colistin dose >1250–1350 mg and total dose/IBW >23.5–24 mg/kg demonstrated significant risks of AKI. Conclusion. The incidence of AKI after colistin administration was high and impacted mortality. Prevention and early correction of these related factors are mandatory. Careful use of colistin was also both beneficial in mortality and AKI reductions.


  • Open Access

    A Comparison Between 12 Versus 20 Weeks of Trimethoprim-sulfamethoxazole as Oral Eradication Treatment for Melioidosis: An Open-label, Pragmatic, Multicenter, Non-inferiority, Randomized Controlled Trial

    by Siriluck Anunnatsiri, Wipada Chaowagul, Prapit Teparrukkul, Ploenchan Chetchotisakd, Kittisak Tanwisaid, Supphachoke Khemla, Surapong Narenpitak, Moragot Pattarapongsin, Wirod Kongsawasd, Pornrith Pisuttimarn, et al.

    Treatment of melioidosis comprises intravenous drugs for at least 10 days, followed by oral trimethoprim-sulfamethoxazole (TMP-SMX) for 12 to 20 weeks. Oral TMP-SMX is recommended for 12 weeks in Australia and 20 weeks in Thailand. For this open-label, pragmatic, multicenter, noninferiority, randomized controlled trial, we enrolled patients with culture-confirmed melioidosis who had received oral eradication treatment for 12 weeks and had no clinical evidence of active melioidosis. We randomly assigned patients to stop treatment (12-week regimen) or continue treatment for another 8 weeks (20-week regimen). The primary end point was culture-confirmed recurrent melioidosis within 1 year after enrollment. The noninferiority margin was a hazard ratio (HR) of 2.0. The secondary composite end point, combining overall recurrent melioidosis and mortality, was assessed post hoc. We enrolled 658 patients: 322 to the 12-week regimen and 336 to the 20-week regimen. There were 5 patients (2%) in the 12-week regimen and 2 patients (1%) in the 20-week regimen who developed culture-confirmed recurrent melioidosis (HR, 2.66; 95% confidence interval [CI], .52–13.69). The criterion for noninferiority of the primary event was not met (1-sided P = .37). However, all-cause mortality was significantly lower in the 12-week regimen group than in the 20-week regimen group (1 [.3%] vs 11 [3%], respectively; HR, 0.10; 95% CI, .01–.74). The criterion for noninferiority of the secondary composite end point, combining overall recurrent melioidosis and mortality, was met (1-sided P = .022). Based on the lower total mortality and noninferiority of the secondary composite end point observed, we recommend the 12-week regimen of TMP-SMX for oral eradication treatment of melioidosis. NCT01420341.


  • Open Access

    Melioidosis in Thailand: Present and Future

    by Soawapak Hinjoy, Viriya Hantrakun, Somkid Kongyu, Jedsada Kaewrakmuk, Tri Wangrangsimakul, Siroj Jitsuronk, Weerawut Saengchun, Saithip Bhengsri, Thantapat Akarachotpong, Somsak Thamthitiwat, et al.

    A recent modelling study estimated that there are 2800 deaths due to melioidosis in Thailand yearly. The Thailand Melioidosis Network (formed in 2012) has been working closely with the Ministry of Public Health (MoPH) to investigate and reduce the burden of this disease. Based on updated data, the incidence of melioidosis is still high in Northeast Thailand. More than 2000 culture-confirmed cases of melioidosis are diagnosed in general hospitals with microbiology laboratories in this region each year. The mortality rate is around 35%. Melioidosis is endemic throughout Thailand, but it is still not uncommon that microbiological facilities misidentify Burkholderia pseudomallei as a contaminant or another organism. Disease awareness is low, and people in rural areas neither wear boots nor boil water before drinking to protect themselves from acquiring B. pseudomallei. Previously, about 10 melioidosis deaths were formally reported to the National Notifiable Disease Surveillance System (Report 506) each year, thus limiting priority setting by the MoPH. In 2015, the formally reported number of melioidosis deaths rose to 112, solely because Sunpasithiprasong Hospital, Ubon Ratchathani province, reported its own data (n = 107). Melioidosis is truly an important cause of death in Thailand, and currently reported cases (Report 506) and cases diagnosed at research centers reflect the tip of the iceberg. Laboratory training and communication between clinicians and laboratory personnel are required to improve diagnosis and treatment of melioidosis countrywide. Implementation of rapid diagnostic tests, such as a lateral flow antigen detection assay, with high accuracy even in melioidosis-endemic countries such as Thailand, is critically needed. Reporting of all culture-confirmed melioidosis cases from every hospital with a microbiology laboratory, together with final outcome data, is mandated under the Communicable Diseases Act B.E.2558. By enforcing this legislation, the MoPH could raise the priority of this disease, and should consider implementing a campaign to raise awareness and melioidosis prevention countrywide.


  • Predictive Model for Permanent Shunting in Cryptococcal meningitis

    by Woralux Phusoongnern, Siriluck Anunnatsiri, Kittisak Sawanyawisuth, Amnat Kitkhuandee

    Cryptococcal meningitis may have long-term morbidity and requires a permanent cerebrospinal fluid shunt. This study aimed to evaluate the risk factors and create a predictive model for permanent shunt treatment in cryptococcal meningitis patients. This was a retrospective analytical study conducted at Khon Kaen University. The study period was from January 2005 to December 2015. We enrolled all adult patients diagnosed with cryptococcal meningitis. Risk factors predictive for permanent shunting treatment were analyzed by multivariate logistic regression analysis. There were 341 patients diagnosed with cryptococcal meningitis. Of those, 64 patients (18.7%) were treated with permanent shunts. There were three independent factors associated with permanent shunt treatment. The presence of hydrocephalus had the highest adjusted odds ratio at 56.77. The resulting predictive model for permanent shunt treatment (y) is (−3.85) + (4.04 × hydrocephalus) + (2.13 × initial cerebrospinal fluid (CSF) opening pressure (OP) > 25 cm H2O) + (1.87 × non-human immune deficiency vrus (HIV)). In conclusion, non-HIV status, initial CSF OP greater than or equal to 25 cm H2O, and the presence of hydrocephalus are indicators of the future necessity for permanent shunt therapy.


    • 1 September 2012
      • Vol. 43  (5) , 1169-77

    Risk factors and clinical outcomes of extended spectrum beta-lactamase (ESBL)-producing Escherichia coli septicemia at Srinagarind University Hospital, Thailand.

    by Siriluck Anunnatsiri, Patapong Towiwat, Prajuab Chaimanee

    Escherichia coli producing extended spectrum beta-lactamase (ESBL) has emerged as a worldwide, public health problem. The aims of this study were to determine the incidence of ESBL-producing E. coli septicemia and evaluate the factors associated with the infection and the clinical outcomes. We reviewed 145 cases of E. coli septicemia among adult patients admitted to Srinagarind University Hospital in northeastern Thailand between 2005 and 2006. The incidence of ESBL-producing E. coli septicemia was 9.9 cases per 10,000 hospital admissions. The factors significantly associated with ESBL-producing E. coli septicemia were: 1) hospital acquisition [odds ratio (OR) 6.46; 95% confidence interval (CI) 2.01-20.79], 2) previous use of a fluoroquinolone, (OR 19.14; 95% CI 5.82-62.96), and 3) use of a central venous catheter (OR, 8.59; 95% CI, 1.11-66.27). Seventy-two hours after receiving empiric treatment, a significantly greater proportion of patients with ESBL-producing E. coli septicemia had a worse clinical outcome than those with non-ESBL producing E. coli septicemia (p = 0.01). The overall mortality rate was significantly higher among the ESBL-producing E. coli septicemia group than the non-ESBL producing E. coli septicemia group (29% vs 11.5%, respectively, p = 0.02). A high APACHE II score, ESBL-producing E. coli septicemia, primary septicemia, and having a non-urinary tract infecting as a source of septicemia were significantly independent factors related to mortality among patients with E. coli septicemia. ESBL-producing E. coli septicemia is an important cause of nosocomial infection and is related to higher mortality risk, especially among those with primary septicemia and secondary septicemia due to a non-urinary tract infection.


    • 1 July 2012
      • p. S143-8

    Burden of human immunodeficiency virus (HIV) infection in hospitalized Thai adults: an analysis of data from the National Health Insurance System 2010.

    by Anunnatsiri Siriluck, Yupa Thavornpitak

    Human immunodeficiency virus (HIV) infection continues to be a major health problem worldwide. Whether several intervention programs are successful enough to ameliorate the significant hospitalization burden created by these patients is not known. To analyze the burden of HIV infection on patient-hospitalization and death in the adult population using in-patient information from the three health insurance coverage schemes from the fiscal year 2010. The authors analyzed the data on in-patients with ICD-10 coding B20-B24 HIV disease to obtain the admission and mortality rate, length of hospital stay and hospital charges. The admission rate among adult HIV-infected patients was 91.8 times per 100,000 adult population. The most common age group affected by the disease was the 26-40 year-olds (59%). The most common condition causing hospitalization was opportunistic infection (83.6%), of which tuberculosis was the highest. The mortality rate was 10.3% and increasing with age. AIDS-related symptoms, malignancy and opportunistic infections were the major impacts on mortality. HIV/AIDS still constitutes a major disease burden among the adult Thai population. Increased public awareness and prevention and access to early HIV diagnosis and treatment could be key factors for lowering the burden of disease and improving clinical outcomes.

    • 1 May 2011
      • Vol. 42  (3) , 693-703

    Risk factors and clinical outcomes of multidrug-resistant Acinetobacter baumannii bacteremia at a university hospital in Thailand.

    by Siriluck Anunnatsiri, Pantipa Tonsawan

    Multidrug-resistant (MDR) Acinetobacter baumannii has become a major cause of hospital-acquired infection worldwide. There are few papers regarding this particular subject. Our aim was to assess the incidence of bacteremia due to MDR Acinetobacter baumannii, factors associated with the infection, and clinical outcomes. We studied 49 cases of A. baumannii bacteremia in adult patients admitted to a university hospital in Northeast Thailand between 2005 and 2007. The incidence of MDR A. baumannii bacteremia was 3.6 episodes per 10,000 hospital admissions. Significantly independent factors associated with MDR A. baumannii bacteremia were previous: 1) ICU admission [odds ratio (OR) 10.01; 95% confidence interval (CI) 1.39-72.20]; 2) use of beta-lactam/beta-lactamase inhibitor antibiotics (OR 8.06; 95%CI 1.39-46.64); and 3) use of a carbapenem antibiotics (OR 11.40; 95%CI 1.44-89.98). The overall mortality rate was significantly higher in the MDR group than in the susceptible group (91.7% vs 48%, respectively) (p=0.001). The significantly independent factors related to mortality were: 1) APACHE II score (OR 1.25; 95%CI 1.03-1.52) and 2) secondary bacteremia (OR 14.86; 95%CI 1.37-161.90). This study revealed the significantly independent factors associated with MDR A. baumannii bacteremia were prior ICU admission and prior use of broad spectrum antibiotics. This infection has a high mortality rate. Emphasis needs to be on prevention, strict application of infection control and appropriate use of antibiotics.


  • Fungemia in non-HIV-infected patients: a five-year review

    by Siriluck Anunnatsiri, Ploenchan Chetchotisakd, Piroon Mootsikapun